Kamata Masakazu, Liu Shirley, Liang Min, Nagaoka Yoshiko, Chen Irvin S Y
Department of Microbiology, Immunology and Molecular Genetics, University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, CA 90095, USA.
Hum Gene Ther. 2010 Nov;21(11):1555-67. doi: 10.1089/hum.2010.050. Epub 2010 Oct 6.
The recent development of induced pluripotent stem cells (iPSCs) by ectopic expression of defined reprogramming factors offers enormous therapeutic opportunity. To deliver these factors, murine leukemia virus (MLV)-based vectors have been broadly used in the setting of hematopoietic stem cell transplantation. However, MLV vectors have been implicated in malignancy induced by insertional mutagenesis, whereas lentiviral vectors have not. Furthermore, the infectivity of MLV vectors is limited to dividing cells, whereas lentiviral vectors can also transduce nondividing cells. One important characteristic of MLV vectors is a self-silencing property of the promoter element in pluripotent stem cells, allowing temporal transgene expression in a nonpluripotent state before iPSC derivation. Here we test iPSC generation using a novel chimeric vector carrying a mutant MLV promoter internal to a lentiviral vector backbone, thereby containing the useful properties of both types of vectors. Transgene expression of this chimeric vector was highly efficient compared with that of MLV vectors and was silenced specifically in human embryonic stem cells. Human fetal fibroblasts transduced with the vector encoding each factor were efficiently reprogrammed into a pluripotent state, and these iPSCs had potential to differentiate into a variety of cell types. To explore the possibility of iPSCs for gene therapy, we established iPSC clones expressing a short hairpin RNA (shRNA) targeting chemokine receptor 5 (CCR5), the main coreceptor for HIV-1. Using a reporter construct for CCR5 expression, we confirmed that CCR5 shRNA was expressed and specifically knocked down the reporter expression in iPSCs. These data indicate that our chimeric lentiviral vector is a valuable tool for generation of iPSCs and the combination with vectors encoding transgenes allows for rapid establishment of desired genetically engineered iPSC lines.
通过异位表达特定重编程因子诱导多能干细胞(iPSC)的最新进展提供了巨大的治疗机会。为了递送这些因子,基于鼠白血病病毒(MLV)的载体已广泛用于造血干细胞移植。然而,MLV载体与插入诱变诱导的恶性肿瘤有关,而慢病毒载体则没有。此外,MLV载体的感染性仅限于分裂细胞,而慢病毒载体也可以转导非分裂细胞。MLV载体的一个重要特征是多能干细胞中启动子元件的自我沉默特性,允许在iPSC衍生之前在非多能状态下进行瞬时转基因表达。在这里,我们使用一种新型嵌合载体测试iPSC的生成,该载体在慢病毒载体骨架内携带突变的MLV启动子,从而兼具两种载体的有用特性。与MLV载体相比,这种嵌合载体的转基因表达效率很高,并且在人胚胎干细胞中特异性沉默。用编码每个因子的载体转导的人胎儿成纤维细胞被有效地重编程为多能状态,并且这些iPSC具有分化为多种细胞类型的潜力。为了探索iPSC用于基因治疗的可能性,我们建立了表达靶向趋化因子受体5(CCR5)的短发夹RNA(shRNA)的iPSC克隆,CCR5是HIV-1的主要共受体。使用CCR5表达的报告构建体,我们证实CCR5 shRNA在iPSC中表达并特异性敲低报告基因表达。这些数据表明,我们的嵌合慢病毒载体是生成iPSC的有价值工具,并且与编码转基因的载体组合可以快速建立所需的基因工程iPSC系。